Ensysce Biosciences (NASDAQ:ENSC) has received a $5.3 million award from the National Institute on Drug Abuse (NIDA), completing a multi-year federal grant totaling $15.1 million to support development of its Breakthrough Therapy-designated opioid candidate PF614-MPAR.
Key Investor Takeaways
- Ensysce Biosciences (NASDAQ:ENSC) received a $5.3 million NIDA funding award, completing a three-year federal grant totaling $15.1 million.
- The funding will support completion of the PF614-MPAR 102 clinical study and non-clinical work required for a future New Drug Application (NDA).
- PF614-MPAR has received FDA Breakthrough Therapy designation for its opioid overdose protection approach.
- The company’s MPAR technology is designed to limit opioid release when excessive oral doses are taken while maintaining therapeutic exposure under prescribed use.
- Ensysce also plans to expand its TAAP and MPAR platforms into additional therapeutic areas, including ADHD and opioid use disorder.
Why ENSC Stock Is in Focus
Ensysce announced it has received a Notice of Award for $5.3 million from NIDA, representing the third and final installment of a federal grant program totaling $15.1 million.
According to the company, the funding will be used to complete the PF614-MPAR 102 clinical study and the long-term non-clinical studies needed to support a future NDA submission for PF614-MPAR.
PF614-MPAR is the company’s lead opioid candidate and incorporates its proprietary Multi-Pill Abuse Resistance (MPAR) technology. The drug previously received FDA Breakthrough Therapy designation following review of clinical data from the PF614-101 study.
Ensysce said the technology is designed to maintain therapeutic opioid exposure under normal use while limiting additional opioid release if excessive oral doses are ingested.
Why This Matters for Investors
The latest funding provides non-dilutive capital to support continued clinical and regulatory development of Ensysce’s lead drug candidate.
Completion of the full $15.1 million federal award may reduce funding pressure for the PF614-MPAR program as it advances toward later-stage development and eventual regulatory submission. Continued support from NIDA also reflects ongoing government backing for research into technologies aimed at reducing opioid misuse and overdose risk.
The company also believes its TAAP and MPAR platforms could have applications beyond pain management. If development progresses successfully, those technologies may support additional pipeline opportunities in areas including ADHD and opioid use disorder.
What to Watch Next
Investors will likely monitor:
- Completion of the PF614-MPAR 102 clinical study.
- Progress on the non-clinical studies supporting a future NDA submission.
- Additional regulatory interactions for the Breakthrough Therapy-designated program.
- Clinical updates for PF614-MPAR and the broader MPAR platform.
- Development of TAAP and MPAR technologies in additional therapeutic indications.